APCM Wealth Management for Individuals Takes $453,000 Position in Becton Dickinson and Co (BDX)

APCM Wealth Management for Individuals purchased a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,892 shares of the medical instruments supplier’s stock, valued at approximately $453,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Chicago Equity Partners LLC acquired a new stake in Becton Dickinson and during the 1st quarter worth $271,000. ING Groep NV acquired a new stake in Becton Dickinson and during the 1st quarter worth $423,000. Thrivent Financial for Lutherans boosted its stake in Becton Dickinson and by 2.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 12,204 shares of the medical instruments supplier’s stock worth $2,645,000 after purchasing an additional 272 shares during the period. King Luther Capital Management Corp acquired a new stake in Becton Dickinson and during the 1st quarter worth $242,000. Finally, ProVise Management Group LLC boosted its stake in Becton Dickinson and by 24.6% during the 1st quarter. ProVise Management Group LLC now owns 2,267 shares of the medical instruments supplier’s stock worth $491,000 after purchasing an additional 447 shares during the period. 86.96% of the stock is owned by institutional investors.

Shares of Becton Dickinson and stock opened at $260.63 on Monday. The firm has a market cap of $69.13 billion, a price-to-earnings ratio of 24.75, a PEG ratio of 1.76 and a beta of 1.10. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a one year low of $191.53 and a one year high of $263.37.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. Becton Dickinson and’s quarterly revenue was up 41.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. equities research analysts forecast that Becton Dickinson and Co will post 11.01 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a yield of 1.15%. Becton Dickinson and’s payout ratio is currently 31.65%.

A number of analysts recently weighed in on BDX shares. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Tuesday, May 29th. JPMorgan Chase & Co. upgraded shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective for the company in a research report on Thursday, June 21st. KeyCorp restated a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada restated a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, Citigroup upped their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Becton Dickinson and has an average rating of “Buy” and a consensus target price of $251.64.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: Hedge Funds – How They Work For Investors

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply